Internal medicine (Tokyo, Japan)最新文献_第4页

A Transfusion-transmitted Chronic Hepatitis E Virus Infection after Allogeneic Bone Marrow Transplantation with Viral Clearance Following Immunosuppression Tapering. 输血传播的慢性戊型肝炎病毒感染异体骨髓移植后病毒清除免疫抑制逐渐减少。

IF 1.1

Internal medicine (Tokyo, Japan) Pub Date : 2026-10-15 Epub Date: 2026-03-03 DOI: 10.2169/internalmedicine.6903-25

Keijiro Sato, Hiroko Kazumoto, Ami Tanaka, Hidekatsu Sakata, Shunya Sunohara, Shintaro Kazama, Hiroko Kaiume, Hiromitsu Mori, Toshimitsu Ueki

引用次数: 0

Late-onset Acute Cellular Rejection after Lung Transplantation Triggered by a Fluctuation in the Tacrolimus Trough Level Which Was Successfully Treated with Steroid Pulse Therapy. 他克莫司谷水平波动引发肺移植后迟发性急性细胞排斥反应，经类固醇脉冲治疗成功。

IF 1.1

Internal medicine (Tokyo, Japan) Pub Date : 2026-10-15 Epub Date: 2026-03-17 DOI: 10.2169/internalmedicine.6307-25

Ayaka Sugiura, Kensuke Kanaoka, Maiko Naito, Takashi Kanou, Takayuki Shiroyama, Kotaro Miyake, Haruhiko Hirata, Takahiro Matsui, Yoshito Takeda, Yasushi Shintani, Atsushi Kumanogoh

引用次数: 0

Changes in Gait Speed During a 12-Month Multidisciplinary Obesity Management Program Including Semaglutide: A Real-World Observational Study in Japanese Adults With Musculoskeletal Disorders. 在包括西马鲁肽在内的12个月多学科肥胖管理项目中步态速度的变化：一项对日本成人肌肉骨骼疾病的真实世界观察研究。

IF 1.1

Internal medicine (Tokyo, Japan) Pub Date : 2026-10-15 DOI: 10.2169/internalmedicine.8145-26

Masuomi Tomita, Fumiya Harashima, Naoto Takeda, Chikako Ishida, Kazuhito Nagasaki, Kyota Kikuchi, Katsuya Hisamichi

{"title":"Changes in Gait Speed During a 12-Month Multidisciplinary Obesity Management Program Including Semaglutide: A Real-World Observational Study in Japanese Adults With Musculoskeletal Disorders.","authors":"Masuomi Tomita, Fumiya Harashima, Naoto Takeda, Chikako Ishida, Kazuhito Nagasaki, Kyota Kikuchi, Katsuya Hisamichi","doi":"10.2169/internalmedicine.8145-26","DOIUrl":"https://doi.org/10.2169/internalmedicine.8145-26","url":null,"abstract":"Background　Obesity is associated with musculoskeletal disorders, impaired mobility, and frailty. While semaglutide induces substantial weight loss, its effects on objectively measured physical function in routine clinical practice are unclear. We investigated the changes in gait speed and physical function during a multidisciplinary obesity management program that included semaglutide.Methods　This retrospective observational study included 22 adults with obesity and musculoskeletal disorders who completed a 12-month multidisciplinary obesity management program. The program included nutritional counseling every two months, physical therapist-guided exercise intervention, and semaglutide treatment. The primary outcome was the usual gait speed. The secondary outcomes included body weight, pain score, step count, muscle function, and body composition.Results　Body weight decreased significantly from 89.2±18.6 kg to 81.5±17.3 kg (p<0.001). Usual gait speed improved significantly from 0.77±0.20 m/s to 0.91±0.19 m/s (p<0.001). Pain scores also significantly improved (p<0.001). Improvements in gait speed were not associated with weight loss (r=0.22, p=0.32) or pain reduction (r=-0.04, p=0.84). Baseline gait speed was inversely associated with gait speed improvement (r=-0.44, p=0.043), indicating greater gains in participants with poorer baseline mobility.Conclusions　A 12-month multidisciplinary obesity management program, including semaglutide, significantly improved gait speed in patients with obesity and musculoskeletal disorders. Greater improvements were observed in participants with impaired baseline mobility. These findings support the evaluation of obesity treatment not only by weight loss, but also by recovery of mobility.","PeriodicalId":520650,"journal":{"name":"Internal medicine (Tokyo, Japan)","volume":" ","pages":""},"PeriodicalIF":1.1,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149187846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Rare Case of Slowly Progressive Meningitis Caused by Streptococcus intermedius. 由中间链球菌引起的缓慢进展性脑膜炎1例。

IF 1.1

Internal medicine (Tokyo, Japan) Pub Date : 2026-10-15 Epub Date: 2026-03-17 DOI: 10.2169/internalmedicine.6465-25

Yuri Kawano, Toshitaka Kamon, Rika Hagihara, Nobuo Ito

引用次数: 0

Lung Cancer Initially Presenting with Diffuse Alveolar Damage and Brain Infarction: An Autopsy Case Report. 肺癌最初表现为弥漫性肺泡损伤和脑梗死：一个尸检病例报告。

IF 1.1

Internal medicine (Tokyo, Japan) Pub Date : 2026-10-15 Epub Date: 2026-03-17 DOI: 10.2169/internalmedicine.6806-25

Taiki Ikeda, Yoshiaki Kinoshita, Masayo Yoshimura, Michiko Nakashima, Kengo Takata, Keita Hara, Chiharu Hirai, Takuhide Utsunomiya, Shota Nakashima, Hisako Kushima, Satoshi Nimura, Hiroshi Ishii

引用次数: 0

Cerebral Attack With Cortical-Leptomeningeal Involvement and Seizures in AQP4-IgG-Positive Neuromyelitis Optica Spectrum Disorder. aqp4 - igg阳性神经脊髓炎视谱障碍伴皮质-轻脑膜受累和癫痫发作。

IF 1.1

Internal medicine (Tokyo, Japan) Pub Date : 2026-10-15 DOI: 10.2169/internalmedicine.7994-26

Miyuki Miyamoto, Yuma Sato, Nobuyuki Ishii

引用次数: 0

Trends and Factors Associated with LDL-C Treatment Target Attainment Rates among Patients with Secondary Prevention Setting of Atherosclerotic Cardiovascular Disease: Assessments from Japanese Health Checkup Data. 动脉粥样硬化性心血管疾病二级预防患者LDL-C治疗目标达成率的趋势和相关因素：来自日本健康检查数据的评估

IF 1.1

Internal medicine (Tokyo, Japan) Pub Date : 2026-10-15 Epub Date: 2026-02-24 DOI: 10.2169/internalmedicine.6925-25

Atsushi Furukawa, Hayato Tada, Kenji Sakata, Soichiro Usui, Masayuki Takamura

{"title":"Trends and Factors Associated with LDL-C Treatment Target Attainment Rates among Patients with Secondary Prevention Setting of Atherosclerotic Cardiovascular Disease: Assessments from Japanese Health Checkup Data.","authors":"Atsushi Furukawa, Hayato Tada, Kenji Sakata, Soichiro Usui, Masayuki Takamura","doi":"10.2169/internalmedicine.6925-25","DOIUrl":"10.2169/internalmedicine.6925-25","url":null,"abstract":"Objective According to the latest Japanese Guidelines for the Prevention of Atherosclerotic Disease, the target for secondary prevention of low-density lipoprotein cholesterol (LDL-C) is <100 mg/dL in patients with coronary artery disease and <70 mg/dL in patients with acute coronary syndrome, familial hypercholesterolemia, diabetes, or atherothrombotic cerebral infarction. However, it is still unclear if the LDL-C treatment target attainment rates are in an upward trend and what are the factors associated with target attainment. This study aimed to investigate the trends and factors associated with LDL-C treatment target attainment. Methods Using the Health Checkup data in Kanazawa City in 2008, 2012, 2017, and 2022 (n = 38,146-51,969), we analyzed the trends of secondary prevention of LDL-C treatment target attainment rates using the Cochran-Armitage trend test and the factors associated with target attainment by a logistic regression analysis from the 2022 health examination. Results We found that the attainment rates showed a significant upward trend over time (p<0.001), and we also found that a male sex (odds ratio: 2.64, 95% confidence interval: 1.72-4.06, p<0.001) and several lifestyle factors, such as walking or any equivalent amount of physical activity for more than one hour a day, were significantly associated with LDL-C target attainment. Conclusion The LDL-C treatment target attainment rates tended to increase over time, and several factors were associated with LDL-C target attainment.","PeriodicalId":520650,"journal":{"name":"Internal medicine (Tokyo, Japan)","volume":" ","pages":"2666-2670"},"PeriodicalIF":1.1,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147278137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Case of Deep Cerebral Vein Thrombosis Which Is a Treatable Type of Dementia. 脑深部静脉血栓形成是一种可治疗的痴呆症。

IF 1.1

Internal medicine (Tokyo, Japan) Pub Date : 2026-10-15 Epub Date: 2026-03-03 DOI: 10.2169/internalmedicine.6932-25

Miharu Yanagida, Yasushi Hosoi, Hisaya Hiramatsu, Michiko Ito

引用次数: 0

Effectiveness and Safety of Immunosuppressive Therapy in Recurrent Autoimmune Pancreatitis. 免疫抑制治疗复发性自身免疫性胰腺炎的有效性和安全性。

IF 1.1

Internal medicine (Tokyo, Japan) Pub Date : 2026-10-15 Epub Date: 2026-03-03 DOI: 10.2169/internalmedicine.6646-25

Yusuke Kurita, Kensuke Kubota, Ryusuke Yoshimi, Yuji Fujita, Emiko Tanida, Yu Honda, Takeshi Iizuka, Shin Yagi, Sho Hasegawa, Noritoshi Kobayashi, Masato Yoneda

{"title":"Effectiveness and Safety of Immunosuppressive Therapy in Recurrent Autoimmune Pancreatitis.","authors":"Yusuke Kurita, Kensuke Kubota, Ryusuke Yoshimi, Yuji Fujita, Emiko Tanida, Yu Honda, Takeshi Iizuka, Shin Yagi, Sho Hasegawa, Noritoshi Kobayashi, Masato Yoneda","doi":"10.2169/internalmedicine.6646-25","DOIUrl":"10.2169/internalmedicine.6646-25","url":null,"abstract":"Objective Autoimmune pancreatitis (AIP) is a distinct type of chronic pancreatitis that responds well to glucocorticoid therapy. However, some patients experience frequent relapses or become glucocorticoid-dependent. In Western countries, immunosuppressive agents such as azathioprine are widely used to maintain remission. In contrast, evidence for the use of immunosuppressive agents for AIP is limited in Japan and other Asian countries. Therefore, this study aimed to evaluate the efficacy and safety of immunosuppressive agents in patients with refractory AIP. Methods We retrospectively analyzed 12 Japanese patients with type 1 AIP who experienced two or more documented relapses and received immunosuppressive therapy. Clinical remission, adverse events, and the incidence of malignancy were assessed. Results Among 199 patients with AIP treated between 2006 and 2024, 12 (6.0%) with multiple relapses were administered immunosuppressive agents, including azathioprine (n=9), tacrolimus (n=2), and methotrexate (n=1). Nine patients continued therapy for at least two months; of these, eight (88.9%) maintained clinical remission without relapse during treatment. One patient relapsed. However, three patients (25.0%) were unable to continue therapy due to adverse events. Two patients developed malignancies during the long-term follow-up: one with malignant lymphoma and the other with small cell lung cancer. Conclusion Immunosuppressive therapy may contribute to the maintenance of remission in some AIP patients with glucocorticoid-dependent or repeated relapses, even among Japanese patients. However, adverse events led to treatment discontinuation in 25% of patients, and two developed malignancies during follow-up. These findings underscore the need for careful patient selection, individualized risk-benefit evaluation, and ongoing monitoring.","PeriodicalId":520650,"journal":{"name":"Internal medicine (Tokyo, Japan)","volume":" ","pages":"2658-2665"},"PeriodicalIF":1.1,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147358518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Salmonella Osteomyelitis with Cutaneous Fistula in an Immunocompetent Adult Presenting as a Tumor-like Bone Lesion. 沙门氏菌骨髓炎伴皮瘘的免疫正常成人表现为肿瘤样骨病变：1例报告。

IF 1.1

Internal medicine (Tokyo, Japan) Pub Date : 2026-10-15 Epub Date: 2026-03-17 DOI: 10.2169/internalmedicine.6800-25

Taito Sakurai, Kei Furui Ebisawa, Takashi Koyama, Goh Ohji, Kentaro Iwata

引用次数: 0